Supplementation of N-3 LCPUFA to the diet of children older than 2 years: A commentary by the ESPGHAN committee on nutrition

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 1, 2011, Pages 2-10

  Agostoni, Carlo ^a   Braegger, Christian ^b   Decsi, Tamás ^c   Kolacek, Sanja ^d   Mihatsch, Walter ^e   Moreno, Luis A ^f   Puntis, John ^g   Shamir, Raanan ^h   Szajewska, Hania ⁱ   Turck, Dominique ^j   Van Goudoever, Johannes ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF PÉCS   (Hungary)

^d Children's University Hospital Zagreb   (Croatia)

^e Deaconry Hospital   (Germany)

^f UNIVERSITY OF ZARAGOZA   (Spain)

^g LEEDS GENERAL INFIRMARY   (United Kingdom)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

^j UNIV LILLE   (France)

^k EMMA CHILDREN S HOSPITAL   (Netherlands)

more..

Author keywords

attention deficit hyperactivity disorder; commentary; cystic fibrosis; n 3 long chain polyunsaturated fatty acids; phenylketonuria

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; N 3 LONG CHAIN POLYUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG;

ASTHMA; ATTENTION DEFICIT DISORDER; BREAST FEEDING; COGNITION; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFECT; EVOKED VISUAL RESPONSE; HUMAN; NASAL BIOPSY; NONHUMAN; NUTRITION; OUTCOME ASSESSMENT; PATIENT SAFETY; PEDIATRICIAN; PHENYLKETONURIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VISION;

ADOLESCENT; ANIMALS; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE;

EID: 79959833154     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318216f009     Document Type: Review

References (67)

1. Kris-Etherton PM, Innis S. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc 2007;107:1599-611.
2. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academy Press; 2002/2005.
3. Harris WS, Mozaffarian D, Lefevre M, et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 2009;139:804S-19S.
4. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J 2010;8:1461.
5. Gebauer SK, Psota TL, Harris WS, et al. n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am J Clin Nutr 2006;83(6 suppl):1526S-35S.
6. Meyer BJ, Mann NJ, Lewis JL, et al. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 2003;38:391-8. (Pubitemid 36724296)
7. Sioen I, Huybrechts I, Verbeke W, et al. n-6 and n-3 PUFA intakes in pre-school children in Flanders, Belgium. Br J Nutr 2007;98:819-25. (Pubitemid 47487951)
8. Innis SM, Vaghri Z, King DJ. n-6 docosapentaenoic acid is not a predictor of low docosahexaenoic acid status in Canadian preschool children. Am J Clin Nutr 2004;80:768-73.
9. O'Sullivan TA, Ambrosini G, Beilin LJ, et al. Dietary intake and food sources of fatty acids in Australian adolescents. Nutrition 2011;27:153-9.
10. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008;2:CD005169.
11. Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007;1:CD004597.
12. Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007;2:CD006320.
13. McKarney C, Everard M, N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev 2007;4:CD002201.
14. Hartweg J, Perera R, Montori V, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;1:CD003205.
15. Lim AK, Manley KJ, Roberts MA, et al. Fish oil for kidney transplant recipients. Cochrane Database Syst Rev 2007;2:CD005282.
16. Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2007;4:CD003833.
17. Farinotti M, Simi S, Di Pietrantonj C, et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev 2007;1:CD004192.
18. Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;3:CD006443.
19. Simmer K, Schulzke SM, Patole S. Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 2008;1:CD000375.
20. Simmer K, Patole SK, Rao SC. Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 2008;1:CD000376.
21. Koletzko B, Lien E, Agostoni C, et al. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008;36:5-14.
22. Agostoni C, Braegger C, Decsi T, et al. Breast-feeding: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2009;49:112-25.
23. Agostoni C, Decsi T, Fewtrell M, et al. Complementary feeding: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2008;46:99-110.
24. Schuchardt JP, Huss M, Stauss-Grabo M, et al. Significance of longchain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr 2010;169:149-64.
25. Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebocontrolled trial in children and adolescents. J Atten Disord 2009;12: 394-401.
26. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acidcontaining food administration on symptoms of attention-deficit/ hyperactivity disorder-a placebo-controlled double-blind study. Eur J Clin Nutr 2004;58:467-73. (Pubitemid 38443707)
27. Vaisman N, Kaysar N, Zaruk-Adasha Y, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 2008;87:1170-80. (Pubitemid 351679755)
28. Voigt RG, Llorente AM, Jensen CL, et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001; 139:189-96. (Pubitemid 32721703)
29. Bélanger SA, Vanasse M, Spahis S, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health 2009; 14:89-98.
30. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:233-9. (Pubitemid 34038049)
31. Stevens L, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003;38:1007-21. (Pubitemid 37444624)
32. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91. (Pubitemid 46624832)
33. Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot Essent Fatty Acids 2008;78:311-26. (Pubitemid 351794242)
34. Ryan AS, Nelson EB. Assessing the effect of docosahexaenoic acid on cognitive functions in healthy, preschool children: a randomized, placebo-controlled, double-blind study. Clin Pediatr (Phila) 2008; 47:355-62. (Pubitemid 351519654)
35. Dalton A, Wolmarans P, Witthuhn RC, et al. A randomised controlled trial in schoolchildren showed improvement in cognitive function after consuming a bread spread, containing fish flour from a marine source. Prostaglandins Leukot Essent Fatty Acids 2009;80:143-9.
36. Kennedy DO, Jackson PA, Elliott JM, et al. Cognitive and mood effects of 8 weeks' supplementation with 400mg or 1000mg of the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10-12 years. Nutr Neurosci 2009;12:48-56.
37. Osendarp SJ, Baghurst KI, Bryan J, et al. Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia. Am J Clin Nutr 2007;86:1082-93. (Pubitemid 47538312)
38. Muthayya S, Eilander A, Transler C, et al. Effect of fortification with multiple micronutrients and n-3 fatty acids on growth and cognitive performance in Indian schoolchildren: the CHAMPION (Children's Health and Mental Performance Influenced by Optimal Nutrition) Study. Am J Clin Nutr 2009;89:1766-75.
39. Beharry S, Ackerley C, Corey M, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;292:G839-48. (Pubitemid 46440393)
40. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-9. (Pubitemid 38160786)
41. Kurlandsky LE, Bennink MR, Webb PM, et al. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 1994;18:211-7. (Pubitemid 2161378)
42. Van Biervliet S, Devos M, Delhaye T, et al. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 2008;78:109-15. (Pubitemid 351318229)
43. Lloyd-Still JD, Powers CA, Hoffman DR, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006;22:36-46. (Pubitemid 43175783)
44. Panchaud A, Sauty A, Kernen Y, et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 2006;25:418-27. (Pubitemid 43843016)
45. Galli C, Agostoni C, Mosconi C, et al. Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. J Pediatr 1991;119:562-7.
46. Agostoni C, Riva E, Biasucci G, et al. The effects of n-3 and n-6 polyunsaturated fatty acids on plasma lipids and fatty acids of treated phenylketonuric children. Prostaglandins Leukot Essent Fatty Acids 1995;53:401-4. (Pubitemid 26040445)
47. Agostoni C, Scaglioni S, Convissuto M, et al. Biochemical effects of supplemented long-chain polyunsaturated fatty acids in hyperphenylalaninemia. Prostaglandins Leukot Essent Fatty Acids 2001;64: 111-5. (Pubitemid 32234857)
48. Agostoni C, Massetto N, Biasucci G, et al. Effects of long-chain polyunsaturated fatty acid supplementation on fatty acid status and visual function in treated children with hyperphenylalaninemia. J Pediatr 2000;137:504-9.
49. Agostoni C, Verduci E, Massetto N, et al. Long term effects of long chain polyunsaturated fats in hyperphenylalaninemic children. Arch Dis Child 2003;88:582-3. (Pubitemid 36783036)
50. Beblo S, Reinhardt H, Muntau AC, et al. Fish oil supplementation improves visual evoked potentials in children with phenylketonuria. Neurology 2001;57:1488-91. (Pubitemid 32995735)
51. Beblo S, Reinhardt H, Demmelmair H, et al. Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J Pediatr 2007;150:479-84. (Pubitemid 46602320)
52. Peat JK, Salome CM, Woolcock AJ. Factors associated with bronchial hyperresponsiveness in Australian adults and children. Eur Respir J 1992;5:921-9.
53. Hodge L, Salome CM, Peat JK, et al. Consumption of oily fish and childhood asthma risk. Med J Aust 1996;164:137-40. (Pubitemid 26051104)
54. Hodge L, Salome CM, Hughes JM, et al. Effect of dietary intake of omega-3 and omega-6 fatty acids on severity of asthma in children. Eur Respir J 1998;11:361-5. (Pubitemid 28108350)
55. Nagakura T, Matsuda S, Shichijyo K, et al. Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 2000;16:861-5. (Pubitemid 32049372)
56. Reisman J, Schachter HM, Dales RE, et al. Treating asthma with omega- 3 fatty acids: where is the evidence? A systematic review. BMC Complement Altern Med 2006;6:26.
57. Amminger GP, Berger GE, Schäfer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007;61:551-3. (Pubitemid 46185334)
58. Romano C, Cucchiara S, Barabino A, et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005;11: 7118-21. (Pubitemid 43154005)
59. Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006;163:1098-100. (Pubitemid 44464498)
60. Harel Z, Biro FM, Kottenhahn RK, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8. (Pubitemid 26131157)
61. Engler MM, Engler MB, Malloy M, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther 2004;42: 672-9. (Pubitemid 39625126)
62. Engler MM, Engler MB, Arterburn LM, et al. Docosahexaenoic acid supplementation alters plasma phospholipid fatty acid composition in hyperlipidemic children: results from the Endothelial Assessment of Risk from Lipids in Youth (EARLY) study. Nutr Res 2004;24:721-9. (Pubitemid 39421038)
63. Engler MM, Engler MB, Malloy MJ, et al. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 2005;95:869-71. (Pubitemid 40386801)
64. Olgar S, Ertugrul T, Nisli K, et al. Fish oil supplementation improves left ventricular function in chidlren with idiopathic dilated cardiomyopathy. Congest Heart Fail 2007;13:308-12.
65. Thienprasert A, Samuhaseneetoo S, Popplestone K, et al. Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, doubleblind, placebo-controlled intervention trial. J Pediatr 2009;154: 391-5.
66. Alamiz-Echevarria L, Sanjurjo P, Elorz J, et al. Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia. J Inherit Metab Dis 2006;29:58-63.
67. Harel Z, Gascon G, Riggs S, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health 2002;31:154-61. (Pubitemid 34786781)